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Abstract
Background: Lycopene is the main carotenoid in tomatoes, where it is found in high concentrations. Strong
epidemiological evidence suggests that lycopene may provide protection against cardiovascular diseases. We therefore
studied the effects of lycopene on diet-induced increase in serum lipid levels and the initiation of atherosclerosis in New
Zealand White (NZW) rabbits.
Methodology/Principal Findings: The animals, divided into four groups of 9 animals each, were fed either a standard diet, a
high-cholesterol diet containing 0.5% cholesterol, a high-cholesterol diet containing placebo beadlets, or a high-cholesterol
diet plus 5 mg/kg body weight/day of lycopene (in the form of lycopene beadlets), for a period of 4 weeks. We found
significantly elevated lycopene plasma levels in the animal group treated with lycopene beadlets. Compared to the high-
cholesterol and the placebo group, this was associated with a significant reduction of 50% in total cholesterol and LDL
cholesterol serum levels in the lycopene group. The amount of cholesteryl ester in the aorta was significantly decreased by
lycopene. However, we did not observe a significant decrease in the extent of aortic surface lipid accumulation in the
lycopene group. In addition, no differences in the intima-media thickness among groups were observed. Endothelial-
dependent and endothelial-independent vasodilation in isolated rabbit aortic and carotid rings did not differ among any of
the animal groups.
Conclusions: Lycopene supplementation for 4 weeks increased lycopene plasma levels in the animals. Although we found
strongly reduced total and LDL cholesterol serum levels as well as significantly lower amounts of cholesteryl ester in the
aortae in the lycopene-treated group, no significant differences in initial lesions in the aortae were detected.
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Introduction
Epidemiological studies indicate that the consumption of
tomatoes and tomato products is inversely associated with the
prevalence of cardiovascular diseases [1]. Tomatoes contain a
plethora of ingredients. During recent years, the carotenoid
lycopene has attracted much attention for its potentially
beneficial cardiovascular effects [2,3]. Lycopene is located mainly
in tomato peels and contributes to the red colour of tomatoes. A
number of underlying mechanisms for protective cardiovascular
actions of lycopene have been suggested in cell culture studies.
These include inhibition of smooth muscle cell proliferation and
foam cell formation, prevention of endothelial cell injury,
modulation of cholesterol metabolism and inhibition of LDL
oxidation, and decrease of pro-inflammatory cytokines [4].
Antioxidant effects of lycopene are discussed to play a key role
[5]. A number of studies have shown an inverse correlation of
circulating plasma lycopene levels with adverse cardiovascular
parameters in humans. In the Rotterdam study, higher lycopene
serum levels were modestly associated with reduced aortic
calcification [6]. Elevated plasma levels of lycopene correlated
with decreased intima-media thickness in the carotid artery, a
parameter of early stages of atherosclerosis [7–9]. An inverse
relationship between circulating lycopene plasma levels and
arterial stiffness was observed [10,11]. The impact of lycopene on
blood cholesterol levels in human intervention studies appears to
be dose-dependent [12].
Growing evidence from in vitro experiments as well as from
epidemiological and intervention studies on the cardiovascular
beneficial effects of lycopene prompted us to investigate the
impact of lycopene supplementation on diet-induced increase
in serum lipid levels and the initiation of atherosclerosis in New
Zealand White (NZW) rabbits. Rabbits have been widely used
as an animal model for the study of atherosclerosis [13]. After 4
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weight/day of lycopene significantly suppressed high-cholester-
ol induced total and LDL cholesterol levels in serum. In
addition, the amounts of cholesteryl ester in the aortae were
significantly reduced in the animal group fed with lycopene.
The extent of aortic surface lipid deposition was not influenced
by lycopene.
Materials and Methods
Animal experiments
Male New Zealand White (NZW) rabbits from Charles River
Laboratories (Sulzfeld, Germany) at 18 weeks (weight 3.3–
4.1 kg) were used for this experiment. After an adaption period
with standard diet, blood was collected after overnight fasting
from the central ear artery to obtain basal lipid and lycopene
levels. The animals were stratified into four groups (n=9
animals each) based on blood lipid levels and body weights.
The rabbits were housed in individual cages at 20uCu n d e ra
12-hour dark and light cycle. The control group was fed a
standard diet (16.5% protein, 3.5% fat, 15.2% fibre, 7.2% ash,
19.3% starch, 6.5% sugar). The cholesterol group received the
standard diet supplemented with 0.5% cholesterol (high-
cholesterol diet, ssniff Spezialdia ¨ t e nG m b H ,S o e s t ,G e r m a n y ) .
The lycopene group received the high-cholesterol diet supple-
mented with 5 mg/kg body weight/day of lycopene in the form
of lycopene beadlets mixed into the chow. The lycopene
beadlets [redivivo
TM (lycopene) 10% CWS/S-TG] were kindly
provided by DSM Nutritional Products (Basel, Switzerland).
The beadlets contain 10% lycopene in a cornstarch-coated
matrix of modified starch and glucose with a-tocopherol (1.5%)
and sodium ascorbate (5%) for stabilisation of lycopene. An
additional animal group was fed a high-cholesterol diet with
placebo beadlets (DSM Nutritional Products, Basel, Switzer-
land) that contain all the ingredients of lycopene beadlets
except lycopene. All diets were pelletized under low pressure
and low temperature to preserve the integrity of the beadlets.
Both diets with beadlets were sealed under vacuum and stored
with an oxygen adsorber in aliquots at 220uCu n t i lu s e .
Constant lycopene content in the chow was verified during the
experiment. Fresh food was provided every day and chow from
the previous day was removed. Water and food were supplied
ad libitum. Consumption of the diets was determined daily by
weighing the chow. Body weights of the animals were recorded
weekly and supply of the diets was adjusted accordingly. All
diets were administered for 4 weeks. At the end of the study, the
rabbits were anesthetized with pentobarbital sodium (20–
40 mg/kg body weight intravenously) and blood was collected
by heart puncture. Plasma and serum were obtained and frozen
at 280uC for further analysis. Animals were sacrificed with
100 mg/kg body weight pentobarbital intravenously. Aortae
were excised for assessment of atherosclerotic changes,
vasorelaxation studies, and determinations of lipid levels. The
animal study was carried out in strict accordance with national
g u i d e l i n e so nt h ec a r ea n du s eo fl a b o r a t o r ya n i m a l s .T h es t u d y
was approved by the local ethics committee, the Landesamt fu ¨r
Gesundheit und Soziales (LAGeSo) Berlin, under the permit
number G 007/08. All efforts were made to minimize suffering
of animals.
Lycopene plasma levels
Carotenoids were extracted as described [14], with slight
modifications [15]. Echinenone (CaroteNature, Lupsingen,
Switzerland) was used as internal standard. The measurements
were carried out under subdued light to prevent photodegrada-
tion and isomerization. We employed a Merck L7200 auto-
sampler, a Merck L7100 pump, a Merck L7450 PDA detector
(Merck, Darmstadt, Germany), and a Jet Stream Plus column
oven (Jasco, Groß-Umstadt, Germany) for determination of
lycopene plasma levels by HPLC. We analysed 100 mlo fp l a s m a
extracts on a C30 (25064.6 mm, 5 mm) column (YMC,
Dinslaken, Germany), preceded by a C18 ProntoSil 120-5-C18
H( 1 0 64.0 mm, 5 mm) guard column (Bischoff, Leonberg,
Germany) at 1761uC with diode-array detection at 470 nm.
The mobile phase (1.3 ml/min) consisted of methanol (MeOH)
and methyl tert.-butyl ether (MTBE). We applied the following
gradient procedure: (1) initial condition with 90% MeOH and
10% MTBE, (2) a 45-min linear gradient to 40% MeOH and
60% MTBE, (3) 40% MeOH and 60% MTBE for 15 min, (4) a
3-min linear gradient to 90% MeOH and 10% MTBE, (5) 90%
MeOH and 10% MTBE for 7 min. Lycopene was quantified
using (all-E)-lycopene reference material (CaroteNature, Lupsin-
gen, Switzerland). The concentration of the lycopene stock
solution was checked periodically in n-hexane at 472 nm by using
its extinction coefficient E(1%, 1 cm): 3450. The plasma lycopene
levels are given as total lycopene: i.e., as the sum of all detected
lycopene isomers.
Measurement of serum blood lipids
Fasting total cholesterol, LDL cholesterol, HDL cholesterol and
triglycerides in serum were determined using enzymatic methods
with Cobas C701 module (Roche Diagnostics GmbH, Mannheim,
Germany). Selective determination of HDL and LDL cholesterol
utilizes the formation of water soluble complexes with LDL and
dextran sulfate that are resistant to PEG-modified enzymes. Total-,
LDL-, and HDL-cholesteryl esters were cleaved with cholesterol
esterase to yield the respective free cholesterols. Triglycerides were
hydrolyzed by lipoprotein lipase to obtain free glycerol. Free
cholesterols were oxidised by cholesterol oxidase and glycerol by
Figure 1. Plasma total lycopene levels in individual rabbits
after feeding the indicated diets for 4 weeks. Cholesterol: animals
were fed with a high-cholesterol diet (0.5% cholesterol); Placebo: high-
cholesterol diet supplemented with placebo beadlets containing all
ingredients of lycopene beadlets except lycopene; Lycopene: high-
cholesterol diet supplemented with 5 mg lycopene/kg body weight/
day as lycopene beadlets. The number in the graph represents the
mean 6 SD. n=9 animals per group.
doi:10.1371/journal.pone.0030808.g001
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during this oxidation process is proportional to the amount of
cholesterol and glycerol that is subsequently converted by a colour
reaction and measured photometrical. The following enzymatic
assays were used: CHOD-PAP cobasH for total cholesterol, LDL-C
plus second-generation cobasH for LDL cholesterol, HDL-C plus
third-generation cobasH for HDL cholesterol, and GPO-PAP
cobasH for triglycerides. The amounts of serum lipids for the
respective lipid fractions were calculated according to the
instructions of the manufacturer.
Determination of initial aortic lesion area
The aortae were carefully dissected in situ, then excised and
fixed with formalin. They were cut longitudinally and, after
removal of formalin with destilled water and equilibration in 50%
ethanol, the thoracic (2 cm above the diaphragm up to the
Truncus brachiocephalicus) and abdominal (from diaphragm to
1 cm below the A. renalis) aortae were stained en face with
Scarlet R (Sudan IV) for 5 minutes to visualise lipids. The aortae
were subsequently rinsed with 70% ethanol and washed in
distilled water. Stained aortae were photographed with a digital
camera (Canon PowerShot S50). Total aortic area and Sudan IV-
positive area was quantified using ImageJ version 1.36b software.
The Sudan IV-positive area was calculated as percentage of the
total aortic surface area. The analyst was blinded to the
treatments.
Lipid deposition in tissues
Lipid accumulation in left carotid arteries and in the ascending
aorta was evaluated by Oil red O staining (Sudan Red 5B).
Cryosections (5 mm thick) were mounted on slides, fixed in
formalin, washed in distilled water, and equilibrated in 60%
isopropyl ethanol. Slides were then stained in fresh Oil Red O
solution for 10 minutes and differentiated in 60% isopropyl
ethanol. After rinsing with destilled water, slides were stained with
hematoxylin (for staining of nuclei) for 20 seconds, briefly rinsed
with distilled water, blued for 10 minutes under water, and
mounted in Aquatex. The percentage of Oil red O-stained area on
the total surface area was calculated. The amounts of cholesteryl
esters and other lipid subgroups in distal segments of the frozen
thoracic aorta (1 cm above the diaphragm) were determined by
electrospray ionisation tandem mass spectrometry (ESI-MS/MS)
in positive-ion mode by use of a fragment ion of m/z 369, as
described previously [16].
Figure 2. Blood lipid levels after intervention. Box plot of total cholesterol (A) and LDL cholesterol (B) levels in serum after supplementation
with the indicated diets for 4 weeks. The boxes contain 50% of individual values; the middle line within the box represents the median. Total and LDL
cholesterol levels were significantly lower in the lycopene group. *P,0.05 compared to cholesterol and placebo. n=9 animals per group.
doi:10.1371/journal.pone.0030808.g002
Table 1. Serum lipid levels and LDL/HDL quotients.
Total cholesterol LDL cholesterol HDL cholesterol LDL/HDLquotient
Control 31698 631 5 680 . 6 60.5
Cholesterol 11826329 9486330 2656124 4.061.8
Placebo 10786281 10206372 246688 4.361.1
Lycopene 6646286* 5816278* 229697 2.761.2
#
Values (in mg/dl) are mean 6 SD from n=9 animals per group.
*P,0.05 compared to cholesterol and placebo.
#P,0.05 compared to placebo.
doi:10.1371/journal.pone.0030808.t001
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Histological evaluation was done by Elastica van Gieson
staining. The ascending aorta was fixed in formalin and
paraffin-embedded. Six consecutive sections, with an interval of
100 mm between sections, were analysed. Sections (2 mm thick) of
the ascending aorta were stained with resorcin-fuchsin (for staining
of elastic fibres) for 15 minutes, with hematoxylin (staining of
nuclei) for 2 minutes, and picrofuchsin (staining of collagen and
cytoplasm) for 10 minutes, followed by mounting in Entellan.
Stained slides were visualised under a Leitz DM RBE (Leica,
Wetzlar, Germany) light microscope and recorded with an
AxioCam MRc microscope camera (Carl Zeiss MicroImaging,
Go ¨ttingen, Germany). Images were analysed by a blinded analyst
using the software AxioVision Rel 4.8.2 (Carl Zeiss MicroImaging,
Go ¨ttingen, Germany). Mean intima-media thickness (in mm) is
given for individual animals.
Vasorelaxation studies
After 4 weeks of treatment, abdominal aortae (2 cm-sections
below the parts that were used for en face) and right carotid
arteries from the animals were rapidly excised, cleaned of
surrounding tissue, and cut into rings of 2 mm length under
semi-sterile conditions. The rings were then mounted on platinum
hooks in 10 ml jacketed organ baths containing modified Krebs-
Henseleit solution (composition in mM: 144 NaCl, 5.9 KCl, 1.6
CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 11.1 D-
glucose) and 1 mM diclofenac. Tension was gradually adjusted to
2 g for 1 hour. The solution in the bath was kept at 37uC with a
gas mixture of 5% CO2 and 95% O2. Following equilibration and
submaximal pre-contraction with phenylephrine (1 mM for aortic
rings and 0.5 mM for carotid rings), relaxation to increasing
concentrations of the endothelium-dependent vasodilator acetyl-
choline (50 nM to 10 mM) was performed to obtain cumulative
Figure 3. Surface lipid depositions in explanted aortae in the three high-cholesterol groups. Shown are box plots of the extent of lipid
depositions in the thoracic aorta (A), in the abdominal aorta (B), and the sum of thoracic and abdominal aorta (C) as the percentage of lipid
depositions compared to the total aortic surface area. The results were obtained after sudan IV-staining. n=9 animals per group.
doi:10.1371/journal.pone.0030808.g003
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integrity was confirmed by evaluation of endothelium-independent
vasodilation to sodium nitroprusside (SNP; 1 nM to 1 mM).
Markers of oxidative changes
Serum concentrations of monocyte chemoattractant protein-1
(MCP-1) as an inflammatory cardiovascular marker, were
measured by enzyme-linked immunosorbent assays (ELISA;
Cusabio Biotech, Wuhan, China). Lipid peroxidation products
in serum were determined by spectrophotometric measurement of
formation of thiobarbituric-acid reactive substances (TBARS), as
described [17] with slight modifications. Levels of 8-iso-prosta-
glandin F2a (8-iso-PGF2a; 8-isoprostane) as marker for oxidative
stress were measured in plasma. Alkaline hydrolysis was performed
to quantify the sum of free and lipid-esterified 8-iso-PGF2a. Prior
to ELISA analysis, the plasma samples underwent affinity
purification with an 8-isoprostane affinity purification kit (10368;
Cayman Chemical, Ann Arbor, MI, USA). Total content of 8-
isoprostane in plasma was measured by a specific 8-isoprostane
enzyme-linked immunosorbent assay kit according to the instruc-
tions of the manufacturer (516351; Cayman Chemical, Ann
Arbor, MI, USA).
Statistical analysis
Values are expressed as mean 6 SD unless otherwise indicated.
Statistical analysis was performed with SigmaStat Version 3.
Statistic calculations were carried out with One Way ANOVA on
Ranks (Student-Newman-Keuls test) for multiple pairwise com-
parisons of groups when comparing medians and with Bonferroni
t-test when comparing means. Level of significance was accepted
at P#0.05.
Results
There were no significant differences in mean body weights and
blood lipid levels between the animal groups at the beginning of
the study. Within the high-cholesterol fed groups, no significant
differences in uptake of the cholesterol diet were observed during 4
weeks of supplementation. At the end of the experiment, body
weights of the rabbits did not significantly differ among any of the
groups. Significantly elevated lycopene plasma levels were
obtained in rabbits treated with lycopene for 4 weeks, whereas
all other animal groups were devoid of lycopene (Figure 1). Basal
lipid levels in rabbits were very low (Table 1). The high-fat diet
resulted in a rigorous increase in blood lipid concentrations in all
high-cholesterol groups. However, serum lipid levels were
substantially reduced after additional supplementation with
lycopene. We observed a significant reduction to nearly 50% of
the total cholesterol and LDL cholesterol serum levels in the
lycopene group, in comparison to the high-cholesterol and the
placebo groups (Figure 2). Concentrations of HDL cholesterol did
not significantly differ between all high-cholesterol-fed groups.
The LDL/HDL ratio significantly improved in the animals treated
with lycopene, compared to placebo (Table 1).
Although lycopene strongly decreased serum cholesterol levels,
the extent of surface lipid depositions in the aorta was not
significantly reduced by lycopene. We found only a slight trend
towards lower initial lesion area in the abdominal aorta, whereas
no differences in the thoracic aorta were observed between all
high-cholesterol fed animals (Figure 3). The control group
receiving a standard diet did not show any lipid depositions (data
not shown). In contrast, the amounts of cholesteryl ester within the
aorta that were increased after high-cholesterol diet were
significantly reduced in the lycopene group (Figure 4). Levels of
phosphatidylcholine (PC), lysophosphatidylcholine (LPC), phos-
phatidylglycerol (PG), phosphatidylserine (PS), sphingomyelin
(SPM), and free cholesterol (FC) did not differ between treatment
groups (data not shown). No pronounced aortic lesions (Figure 5A)
and no significant increase in aortic intima-media thickness were
observed after high-cholesterol diet (Figure 5B), which illustrates a
pre-atherosclerotic state with the absence of atherosclerotic
changes in the aortae. In addition, Oil red O staining revealed
no lipid deposition in the carotid arteries after 4 weeks of high-
cholesterol diet. Accumulation of lipids within the aortic root was
negligible, and no differences between all high-cholesterol fed
animal groups were detected (data not shown).
Endothelial-dependent and endothelial-independent vasodila-
tion in isolated rabbit aortic rings was measured after 4 weeks of
diets. No differences were found between all animal groups
(Figure 6). Similar results were obtained with isolated rabbit
carotid rings (data not shown). In accordance with the results of
the vasorelaxation experiments, plasma cGMP levels were not
influenced by the high-cholesterol diet and lycopene had no
impact (data not shown). Also, signs of pro-oxidative changes such
as serum levels of monocyte chemoattractant protein-1 (MCP-1)
and lipid peroxidation (TBARS) in serum as well as plasma levels
of 8-isoprostane (8-iso-prostaglandin F2a) were not increased after
the high-cholesterol diet and were not influenced by lycopene
supplementation (data not shown).
Discussion
The main results of our study are that lycopene supplementa-
tion for 4 weeks strongly suppressed diet-induced increases in total
Figure 4. Levels of cholesteryl ester in the aortae of rabbits
after supplementation for 4 weeks. Data are presented as box
plots. The boxes contain 50% of individual values; the middle line
within the box represents the median. The amount of cholesteryl ester
was significantly lower in the lycopene group. *P,0.05 compared to
cholesterol and placebo. n=9 animals per group.
doi:10.1371/journal.pone.0030808.g004
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tion of cholesteryl esters in aortic tissue of rabbits. However, we
observed no significant differences in surface lipid depositions
among all high-cholesterol fed groups. Furthermore, no advanced
atherosclerotic changes in the aortae, increase of pro-oxidant
parameters in serum, or impairments of vasoreactivity in isolated
blood vessels were detected in all animal groups. The latter
findings indicate that the administration of the high-cholesterol
diet for 4 weeks resulted in a very early, initial state of
atherosclerosis in our rabbit model.
High LDL cholesterol levels represent an independent risk
factor for the development and progression of cardiovascular
diseases. For every reduction in 25 mg/dl of LDL cholesterol, the
risk of vascular mortality was reduced by 11% and of major
coronary events, by 16% [18]. A high LDL/HDL ratio is
predictive for adverse cardiovascular events [19,20]. Although
lycopene did not increase HDL cholesterol levels in our study, the
LDL/HDL quotient was improved in comparison to the high-
cholesterol and the placebo groups, further emphasizing a
beneficial cardiovascular profile of lycopene. Similar reductions
of blood lipid levels by lycopene had been observed in two other
rabbit experiments. High-fat induced hyperlipidemia was signif-
icantly suppressed by various doses of lycopene (4 and 8 mg/kg
body weight/day) in New Zealand White rabbits after treatments
for 4 and 8 weeks. However, a slight increase in HDL cholesterol
levels did not reach statistical significance [21]. In the same animal
model of atherosclerosis, supplementation with three doses of
lycopene in the chow for 12 weeks dose-dependently decreased
diet-induced serum total cholesterol and LDL cholesterol levels
and increased HDL cholesterol [22]. In contrast, supplementation
with a lycopene-enriched tomato extract (15 mg/kg body weight/
day lycopene) in the diet for 16 weeks had no effect on plasma
cholesterol levels in Watanabe Heritable Hyperlipidemic (WWHL)
rabbits [23]. The reason for the lack of effects of lycopene in
WWHL rabbits may originate in defective LDL receptors in these
animals [24]. Since lycopene is transported in the blood mainly in
Figure 5. Microphotographs and intima-media thickness of the ascending aortae in individual animals after the indicated diets. (A)
Representative microphotographs of Elastica van Gieson staining of the overall aortic cross-sections for each group (upper panel). Magnification of
aortic sections (lower panel). (B) Mean intima-media thickness per animal in mm. Summary of all stained segments per animal from n=9 animals per
group.
doi:10.1371/journal.pone.0030808.g005
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obtain cardiovascular beneficial effects of lycopene.
What are the mechanisms behind the cholesterol-lowering
effects of lycopene? It should be noticed in this context that basal
cholesterol levels in rabbits are very low. Primarily, lycopene led to
suppressed cholesterol uptake rather than to a reduction of existing
circulating cholesterol levels in these animals. In human
macrophages, lycopene reduced intracellular cholesterol levels by
decreasing the expression of 3-hydroxy-3-methyl glutaryl Coen-
zyme A (HMG-CoA) reductase, a rate-limiting enzyme in
cholesterol biosynthesis [26]. However, expression levels of
HMG-CoA reductase in the liver were not affected by supple-
mentation with lycopene in our animal experiment (data not
shown). Increased faecal cholesterol excretion, together with
reduced liver HMG-CoA reductase activity, was shown after
dietary lycopene intake in rabbits, suggesting decreased intestinal
cholesterol absorption and biosynthesis [22]. Results for the effects
of lycopene on plasma lipid levels in human intervention studies
are not consistent. Supplementation with tomato extract capsules
(4 mg lycopene) daily for 6 months decreased total cholesterol and
LDL cholesterol levels in postmenopausal women [27]. No effects
on blood lipid levels were obtained after supplementation with a
tomato extract containing 15 mg lycopene daily for 8 weeks in
mild hypertensive patients [28]. A recent meta-analysis of human
intervention trials revealed significant reduction in total and LDL
cholesterol only at doses of $25 mg lycopene daily. Doses of
,25 mg lycopene had no effect on cholesterol serum levels. HDL
cholesterol was not changed by lycopene uptake, independently of
dosages applied [12].
Despite markedly reduced serum cholesterol levels, we found no
effects on surface lipid deposition in the aortae of lycopene-
supplemented rabbits. This represents an unexpected result. In the
studies with atherosclerotic NZW rabbits noted above, the
decrease in blood lipid levels was associated with a concomitant
reduction in aortic plaque area in lycopene-treated animals
[21,22]. In one study, the lipid-lowering effects and the extent of
atherosclerotic lesion reduction by lycopene were comparable with
statins [21]. However, there are a number of differences in study
design between these studies und ours. Changes in aortic lesion
size were assessed after 8 and 12 weeks, whereas in our study we
aimed at shorter intervention times. Hu et al. administered the
lycopene intragastrically by catheter inserted into the stomach,
and the high-fat diet consisted of 1% cholesterol, whereas we used
0.5% cholesterol in our study. In addition to determining
cholesterol-lowering effects in plasma, we found that supplemen-
tation with lycopene reduced the amount of cholesteryl ester in the
aorta. This represents a novel and relevant finding. The invasion
of lipids in the aortic tissue is the initial step in plaque progression
and represents a prerequisite for development of advanced aortic
plaques. The reduced accumulation of lipids within the aortic
tissue, as opposed to equal surface deposition, could point to a
beneficial effect of lycopene on further progression of atheroscle-
rotic changes.
Several reasons could potentially explain why we did not
observe reduced aortic surface lipid deposition, in addition to
decreased accumulation of lipids within the aortae. It could be
argued that the lycopene plasma levels obtained in our study were
too low to exert anti-atherogenic effects beyond reduced tissue
lipid levels. The dosage of 5 mg/kg body weight/day of lycopene
for 4 weeks resulted in significantly increased total lycopene
plasma levels (0.27 mM) in our study. This concentration was even
higher in comparison to the study of Hu et al. describing reduced
atherosclerotic lesions in rabbits after supplementation with
lycopene [21]. Another difference of our study represents the
duration of high-cholesterol diet administration. Certainly, longer
intervention times (as 4 weeks used in our study) would result in
more pronounced atherosclerotic lesions. However, our major
objective was to investigate the effects of lycopene on cardiovas-
cular parameters before the establishment of distinct atheroscle-
rotic lesions in the vessels. We therefore decided to conduct our
study for a shorter time period of 4 weeks. We observed very early
(not advanced) signs of atherosclerosis in our animals. These initial
states of atherosclerosis were influenced by lycopene supplemen-
tation. However, in contrast to other studies with longer duration
[29], we did not observe diminished endothelial-dependent
vasodilation in aortic rings after 4 weeks of high-cholesterol diet,
suggesting that longer intervention times may have resulted in
different outcomes.
There are, to date, no prospective human intervention studies
on the effects of lycopene or tomato products on the progression of
atherosclerosis. An inverse correlation of plasma lycopene levels to
cardiovascular events was found in various epidemiological studies
[30,31]. Therefore, it needs to be proven whether supplementation
with lycopene is able to delay the onset of cardiovascular diseases
in humans.
In conclusion, increased lycopene plasma levels after supple-
mentation were associated with reduced total and LDL cholesterol
in serum as well as with lower aortic cholesteryl ester levels in New
Zealand White (NZW) rabbits. However, no significant impact of
lycopene on surface aortic lipid deposition was observed. It is
accordingly still eligible to ascertain the consequences of reduced
Figure 6. In vitro vasorelaxation studies after the animal
experiment. Endothelial-dependent vasodilation induced by acetyl-
choline (Ach, A) and endothelium-independent vasodilation by sodium
nitroprusside (SNP, B) in isolated rabbit aortic rings after treatments
with the indicated diets for 4 weeks. Graphs show relaxation as percent
of maximal contraction. Data are mean 6 SEM from n=9 animals per
group with 4 aortic rings per animal.
doi:10.1371/journal.pone.0030808.g006
Lycopene Lipid Levels in Rabbits
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30808blood cholesterol levels by lycopene on the progression of
cardiovascular diseases in humans.
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